Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
drug1114	Hydroxychloroquine Sulfate Regular dose Wiki	0.50
drug1113	Hydroxychloroquine Sulfate Loading Dose Wiki	0.50
drug3052	zinc Wiki	0.35
drug2732	after-each-case room disinfection Wiki	0.35
drug1708	Other drugs Wiki	0.35
drug2796	daily room disinfection Wiki	0.35
drug805	ECG-Holter Wiki	0.35
drug2921	non interventional Wiki	0.35
drug2202	Sars-Cov-2 serology Wiki	0.35
drug879	Exebacase Wiki	0.35
drug2004	RO6953958 Wiki	0.35
drug524	Cardiac surgery Wiki	0.35
drug1270	Ivermectin Wiki	0.25
drug1592	Niclosamide Wiki	0.25
drug1598	Nitazoxanide Wiki	0.25
drug3005	standard care Wiki	0.20
drug791	Doxycycline Wiki	0.18
drug923	Favipiravir Wiki	0.09
drug1822	Placebo Wiki	0.08
drug1853	Placebo oral tablet Wiki	0.07
drug262	Azithromycin Wiki	0.06
drug1086	Hydroxychloroquine Wiki	0.04

Correlated MeSH Terms (22)

	Name (Synonyms)	Correlation
D010146	Pain NIH	0.35
D001342	Autonomic Nervous System Diseases NIH	0.35
D002658	Developmental Disabilities NIH	0.35
D016470	Bacteremia NIH	0.35
D001416	Back Pain NIH	0.35
D017116	Low Back Pain NIH	0.35
D004696	Endocarditis NIH	0.35
D054969	Primary Dysautonomias NIH	0.35
D065886	Neurodevelopmental Disorders NIH	0.25
D058070	Asymptomatic Diseases NIH	0.25
D012213	Rheumatic Fever NIH	0.25
D001327	Autoimmune Diseases NIH	0.20
D002659	Child Development Disorders, Pervasive NIH	0.20
D003095	Collagen Diseases NIH	0.18
D001321	Autistic Disorder NIH	0.18
D012216	Rheumatic Diseases NIH	0.16
D000067877	Autism Spectrum Disorder NIH	0.14
D001523	Mental Disorders NIH	0.08
D004194	Disease NIH	0.06
D045169	Severe Acute Respiratory Syndrome NIH	0.05
D018352	Coronavirus Infections NIH	0.04
D011014	Pneumonia NIH	0.02

Correlated HPO Terms (8)

	Name (Synonyms)	Correlation
HP:0003418	Back pain HPO	0.35
HP:0100584	Endocarditis HPO	0.35
HP:0012531	Pain HPO	0.35
HP:0003419	Low back pain HPO	0.35
HP:0002960	Autoimmunity HPO	0.20
HP:0000717	Autism HPO	0.18
HP:0000729	Autistic behavior HPO	0.14
HP:0002090	Pneumonia HPO	0.02

There are 8 clinical trials

Clinical Trials

1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

2 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate

To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.

NCT04346667 SARS-CoV-2 Coronavirus Infection Asymptomatic Condition COVID-19 Drug: Hydroxychloroquine Sulfate Regular dose Drug: Hydroxychloroquine Sulfate Loading Dose Drug: Chloroquine Drug: Placebo

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Asymptomatic Diseases

Primary Outcomes

Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7

Measure: RT-PCR negative status

Time: 6-7 days

Secondary Outcomes

Description: Time to progression to next stage of SARS-CoV-2 disease severity index

Measure: Progression of symptoms

Time: 7 days

Description: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).

Measure: Development of Symptoms

Time: 7 days

Description: Drug related adverse events as determined by data safety and monitoring board (DSMB)

Measure: Adverse events

Time: 7 days

3 Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

The primary objective is to determine the clinical efficacy of Chloroquine (CQ) in health care workers with moderate to high risk of exposure to COVID-19 in preventing symptomatic COVID-19 infections. Secondary endpoints will explore the efficacy of CQ in preventing any infection as defined by seroconversion to positive anti-COVID antibody status.

NCT04349371 COVID Drug: Chloroquine Drug: Placebo oral tablet

Primary Outcomes

Description: Symptomatic illness is defined as COVID infection guidelines and confirmed with anti-COVID antibodies that will be done on serum collect at the final visit. Symptoms include fever, chills, muscle pain, cough, shortness of breath, and diarrhea.

Measure: Number of symptomatic illness in at risk healthcare workers

Time: Up to 3 months

Description: Diagnosis is based on symptoms of COVID-19 and confirmatory anti-COVID antibodies and when available, COVID-19 PCR.

Measure: Number of healthcare workers with symptomatic COVID infections

Time: Up to 3 months

Description: Severe illness includes worsening of symptoms.

Measure: Number of severe illness in at risk healthcare workers

Time: Up to 3 months

Secondary Outcomes

Description: Confirmation with polymerase chain reaction (PCR) when available.

Measure: Number of sero-conversions in at risk healthcare workers

Time: Up to 3 months

Description: Adverse events that are NCI-CTCAE Grade 3 or higher will be counted.

Measure: Percentage of patients with adverse events Grade 3 or higher

Time: Up to 3 months

Description: GI intolerance to chloroquine will be documented and recorded.

Measure: Percentage of patients with GI intolerance

Time: Up to 3 months

4 Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate

To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.

NCT04351191 Sars-CoV2 Symptomatic Condition Covid-19 Drug: Hydroxychloroquine Sulfate Regular dose Drug: Hydroxychloroquine Sulfate Loading Dose Drug: Chloroquine Drug: Placebo

Primary Outcomes

Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7

Measure: RT-PCR result

Time: 6th and 7th day

Secondary Outcomes

Description: Time to progression to next stage of SARS-CoV-2 disease severity index

Measure: Progression of symptoms

Time: 7 days

Description: Death

Measure: Mortality

Time: 30 days

5 Novel Treatment Regimens in Treatment of COVID-19

Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

NCT04382846 COVID Corona Virus Infection Drug: Nitazoxanide Drug: Ivermectin Drug: Chloroquine Drug: Azithromycin

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: the number of patients with virological cure

Measure: Number of patients with virological cure

Time: 6 months

6 The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment

Efficacy of Ivermectin and Doxycycline in COVID-19 treatment

NCT04403555 COVID Drug: Ivermectin Drug: Doxycycline Drug: Chloroquine

Primary Outcomes

Description: The number of patients with improvement or mortality

Measure: The number of patients with improvement or mortality

Time: 1 month

7 Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19

Facing the challenge of finding an efficient treatment for COVID-19, the viral pneumonia caused by the Coronavirus SARS-Cov-2, this study intended to test if Chloroquine or Hydroxychloroquine, two drugs with strong in-vitro antiviral role proven by numerous studies and with a well defined safety profile established, for efficacy in treating COVID-19 and improving an ordinal primary outcome composed by a 9-levels scale, which was recomended by the World Health Organization.

NCT04420247 COVID COVID-19 SARS-CoV 2 Coronavirus Corona Virus Infection Drug: Chloroquine Drug: Hydroxychloroquine Other: standard care

MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia

HPO:Pneumonia

Primary Outcomes

Description: 9-levels scale recomended by WHO for studies related to treating COVID-19

Measure: World Health Organization (WHO) 9-levels scale (from 0-8)

Time: Day14

Description: 9-levels scale recomended by WHO for studies related to treating COVID-19, with lower scores meaning better outcomes (0 means at home with no symptoms and

Measure: WHO 9-levels scale (from 0-8)

Time: Day 28

Secondary Outcomes

Description: 28day mortality

Measure: Mortality

Time: Day 28

Description: Days without need of Mechanical Ventilation

Measure: Ventilation free days

Time: Day 28.

Measure: Duration of mechanical ventilation

Time: Day 28.

Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.

Measure: National Early Warning Score (NEWS)

Time: Day 7

Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.

Measure: National Early Warning Score (NEWS)

Time: Day 14

Description: Trigger system aligned to the scale of clinical risk. Minimum score is 0 (better outcome) and maximum score is 20 (worse outcome). The higher the score, the higher the risk.

Measure: National Early Warning Score (NEWS)

Time: Day 28

Measure: ICU Lenght of Stay

Time: Day 28.

Measure: Hospital Lenght of Stay

Time: Day 28.

Measure: Acute Kidney Disease incidence

Time: Day 28.

Measure: Percentage of patients needing Dialysis

Time: Day 28.